Ocugen Advances Toward Key FDA Submission for Vision Therapy

Ocugen announces a rolling BLA submission for its OCU400 gene therapy targeting Retinitis Pigmentosa, a disease with no treatment for 98% of patients. The news boosted its stock by nearly 5%.

Biopharmaceutical firm Ocugen has announced it will initiate the regulatory submission process for its experimental gene therapy, OCU400, to the U.S. Food and Drug Administration (FDA) within the current year. The company plans to utilize a rolling submission pathway for the treatment of Retinitis pigmentosa. This development prompted a share price increase of nearly 5% on Wednesday.

Financial and Operational Updates

The company recently bolstered its financial position and leadership team. In January, Ocugen secured approximately $20.85 million in net proceeds through a capital raise, issuing 15 million new shares at $1.50 each. Management states these funds are intended to support liquidity through the fourth quarter of 2026.

In a separate February move, Rita Johnson-Greene was appointed as the new Chief Financial Officer. Investors can anticipate further operational details when Ocugen releases its fourth-quarter and full-year 2025 financial results on March 4. This update may also provide more clarity on the FDA submission timeline.

Therapy Mechanism and Target Patient Population

OCU400 is a one-time injection designed as a gene therapy for patients diagnosed with Retinitis pigmentosa, an inherited retinal degenerative disease. The treatment specifically targets the underlying genetic mutations responsible for the condition.

According to Ocugen, this disorder affects an estimated 300,000 individuals across the United States and Europe. A critical aspect of the market opportunity is the significant unmet medical need; the company notes that approximately 98% of those affected currently have no available therapeutic options.

Clinical Data and Regulatory Pathway

The rolling Biologics License Application (BLA) submission process allows Ocugen to submit completed sections of its application to the FDA on an ongoing basis, rather than waiting to compile a single, complete package. The firm has previously indicated its goal is to finalize the entire application by the first half of 2026.

Supporting data comes from a two-year clinical study involving 18 participants. Results indicated the therapy was well-tolerated. Furthermore, treated eyes demonstrated either an improvement or a stabilization in visual function when compared to untreated eyes.